companydata.dkcompanydata.dk

Ascendis Pharma Growth Disorders A/S: Financial statements 2022

CVR: 32323677

Source: annual report 2022, Danish Business Authority

01/01/2022 – 31/12/2022

Ascendis Pharma Growth Disorders A/S (CVR 32323677) has filed annual accounts for 2022. In 2022, the company reported a gross profit of EUR -57,035,666 and a net result of EUR -61,381,172 compared with EUR -50,957,882 the year before. Equity in the 2022 report amounted to EUR -201,822,959.

Gross Profit
EUR -57,035,666
Profit/Loss
EUR -61,381,172
Equity
EUR -201,822,959
Total Assets
EUR 13,615,375
Employees
0

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2022--57M EUR-61.4M EUR-201.8M EUR0
2021--47.9M EUR-51M EUR-140.4M EUR0
2020--30.2M EUR-32.1M EUR-89.5M EUR0
2019--17.9M EUR-19M EUR-57.4M EUR0
2018--14.4M EUR-15.3M EUR-38.4M EUR0

Official annual report

View the official annual report directly on the page with a Pro subscription.

Keep an eye on Ascendis Pharma Growth Disorders A/S

Get notified instantly about new financial statements, ownership changes, management changes and status changes.

Set up monitoring

Events in 2022

Ascendis Pharma Growth Disorders A/S: The 2021 annual report is outMay 9, 2022

Ascendis Pharma Growth Disorders A/S has published its annual report for 2021. Gross profit came to DKK -47,933,482, and the net result was DKK -50,957,882.

About Ascendis Pharma Growth Disorders A/S

Ascendis Pharma Growth Disorders A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ASCENDIS PHARMA, CIRCULATORY DISEASES DIVISION A/S and ASCENDIS PHARMA RELAXIN DIVISION A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR -190,726,000 and a net result of EUR -225,725,000 compared with EUR -176,019,000 the year before. Equity in the 2025 report amounted to EUR -723,740,000.

Source: annual report 2025, Danish Business Authority